Acceleron Pharma Inc. (XLRN) and Nabriva Therapeutics plc (NASDAQ:NBRV) Comparison side by side

Both Acceleron Pharma Inc. (NASDAQ:XLRN) and Nabriva Therapeutics plc (NASDAQ:NBRV) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acceleron Pharma Inc. 44 0.00 45.40M -2.76 0.00
Nabriva Therapeutics plc 2 -0.02 59.84M -2.10 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Acceleron Pharma Inc. and Nabriva Therapeutics plc.


Table 2 provides Acceleron Pharma Inc. and Nabriva Therapeutics plc’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Acceleron Pharma Inc. 104,032,997.25% -35.9% -33.4%
Nabriva Therapeutics plc 2,807,939,561.73% -162.3% -117.6%

Risk & Volatility

Acceleron Pharma Inc. has a 1.16 beta, while its volatility is 16.00% which is more volatile than Standard and Poor’s 500. From a competition point of view, Nabriva Therapeutics plc has a 2.4 beta which is 140.00% more volatile compared to Standard and Poor’s 500.


The Current Ratio and a Quick Ratio of Acceleron Pharma Inc. are 19.3 and 19.3. Competitively, Nabriva Therapeutics plc has 5.6 and 5.6 for Current and Quick Ratio. Acceleron Pharma Inc.’s better ability to pay short and long-term obligations than Nabriva Therapeutics plc.

Analyst Ratings

The Recommendations and Ratings for Acceleron Pharma Inc. and Nabriva Therapeutics plc are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acceleron Pharma Inc. 0 2 2 2.50
Nabriva Therapeutics plc 0 0 0 0.00

The average price target of Acceleron Pharma Inc. is $52.25, with potential upside of 29.30%.

Institutional & Insider Ownership

Institutional investors owned 93.6% of Acceleron Pharma Inc. shares and 49.6% of Nabriva Therapeutics plc shares. Acceleron Pharma Inc.’s share owned by insiders are 0.6%. Insiders Competitively, owned 0.61% of Nabriva Therapeutics plc shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acceleron Pharma Inc. 2.78% 3.39% 9.2% 4.8% 4% 0.25%
Nabriva Therapeutics plc -0.21% -1.86% 9.45% 24.35% -11.71% 62.67%

For the past year Acceleron Pharma Inc. was less bullish than Nabriva Therapeutics plc.


On 6 of the 11 factors Acceleron Pharma Inc. beats Nabriva Therapeutics plc.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The companyÂ’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.